Related Experiment Video
Updated: Aug 3, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained
Insights
Implantable cardioverter-defibrillators (ICDs) improve survival for patients with prior heart attacks and low ejection fraction. Identifying these high-risk patients is crucial for preventing sudden cardiac death.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- The MUSTT and MADIT trials demonstrated survival benefits of implantable cardioverter-defibrillators (ICDs).
- These benefits were observed in patients with previous myocardial infarction, left ventricular ejection fraction ≤0.40, and nonsustained ventricular tachycardia (VT).
- Patients who experienced sustained VT induction during electrophysiology studies were key candidates.
Discussion:
- Sudden cardiac death (SCD) prevention relies on identifying and treating patients similar to those in MUSTT/MADIT trials.
- A collaborative approach involving clinicians is essential for effective risk stratification.
- Further research is needed to refine patient subgroup identification for SCD risk.
Key Insights:
- ICDs offer a significant survival advantage in specific post-myocardial infarction patient populations.
- Nonsustained VT and reduced ejection fraction are critical indicators for ICD consideration.
- Electrophysiology study results are vital for confirming sustained VT inducibility.
Outlook:
- Future efforts should focus on precise SCD risk stratification in vulnerable patient groups.
- Industry collaboration is needed to develop more affordable ICDs for prophylactic use.
- Continued research will refine primary prevention strategies for sudden cardiac death.
Abstract:
MUSTT and MADIT have clearly shown the survival benefit of an implantable cardioverter defibrillator (ICD) in patients with previous myocardial infarction, left ventricular ejection fraction < or = 0.40, and nonsustained ventricular tachycardia (VT), and who have had sustained VT induced at electrophysiology study. Progress in primary prevention of sudden cardiac death (SCD) depends on a concerted effort by clinicians to identify and appropriately treat MUSTT/MADIT-type patients; further research to more precisely define patient subgroups at risk for SCD and the willingness of industry to develop a lower priced ICD for prophylactic use are needed.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy V: Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias